Scholar Rock Appoints Gregory J. Carven, PhD, As Vice President Of Antibody Discovery And Protein Sciences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock, a biotechnology company focused on discovering and developing niche modulators that selectively target growth factor activation in the disease microenvironment, today announced the appointment of Gregory J. Carven, PhD, as Vice President of Antibody Discovery and Protein Sciences. Dr. Carven has more than 15 years of antibody discovery and development experience, including his role as co-inventor of Keytruda® (pembrolizumab), the first PD-1 inhibitor for cancer immunotherapy to receive FDA approval. In his leadership role at Scholar Rock, Dr. Carven will direct the company’s discovery and design of therapeutic antibodies as first-in-class niche modulators for fibrotic, musculoskeletal and autoimmune diseases.

Help employers find you! Check out all the jobs and post your resume.

Back to news